leadf
logo-loader
viewScancell Holdings PLC

Scancell Holdings looks to increase the number of UK phase II trial sites for lead drug

The update was provided alongside the firm’s interim results, which charted a busy period for the immunotherapies specialist, one in which it brought on board a new major shareholder, the Vulpes Life Science Fund

Scancell Holdings PLC -

Scancell Holdings PLC (LON:SCLP) said it is increasing the number of clinical sites as it recruits patients to a UK phase II trial for its lead drug, SCIB1 for the skin cancer melanoma.

The update was provided alongside the firm’s interim results, which charted a busy period for the immunotherapies specialist, one in which it brought on board a new major shareholder, the Vulpes Life Science Fund.

Vulpes injected £3.9mln (which will effectively fund Scancell’s R&D effort in the near-term) for its 17% stake.

In its results statement for the six months ended October 31, the firm also flagged up the fact there are now three partners using its AvidiMab technology.

AvidiMab enhances “avidity”, a term used to describe the overall strength of binding between an antibody and an antigen.

Modifications made using the platform induce the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies and potentially increases their potency.

“Our new AvidiMab platform has generated significant interest and we have signed three agreements with different partners to evaluate its potential, that if successful, could translate into important commercial deals," said chief executive Cliff Holloway.

Turning Scancell’s pipeline, preparations around two other drug candidates – SCIB2 (targeting lung cancer) and Modi-1 (solid tumours) – are designed to usher them into the clinic.

The financials showed the company posted a loss of £3.1mln for the six months. As at October 31 it had £5.8mln in the bank.

Quick facts: Scancell Holdings PLC

Price: 11.6 GBX

LSE:SCLP
Market: LSE
Market Cap: £94.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read